CN110384240A - Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application - Google Patents

Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application Download PDF

Info

Publication number
CN110384240A
CN110384240A CN201910708111.0A CN201910708111A CN110384240A CN 110384240 A CN110384240 A CN 110384240A CN 201910708111 A CN201910708111 A CN 201910708111A CN 110384240 A CN110384240 A CN 110384240A
Authority
CN
China
Prior art keywords
vitamin
hypoglycemic
probiotics fermention
alimentation composition
object powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910708111.0A
Other languages
Chinese (zh)
Inventor
顾茂健
苏健梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xuan Tai Bio Tech Ltd Shanghai
Original Assignee
Xuan Tai Bio Tech Ltd Shanghai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xuan Tai Bio Tech Ltd Shanghai filed Critical Xuan Tai Bio Tech Ltd Shanghai
Priority to CN201910708111.0A priority Critical patent/CN110384240A/en
Publication of CN110384240A publication Critical patent/CN110384240A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention discloses a kind of hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application, the component including parts by weight: 10 parts~15 parts of vitamin mixed powder, 1~5 part of probiotics fermention object powder, 0.5 part~70 parts of sugar alcohol.The present invention is safe and healthy, can enter blood by buccal absorption in Orally disintegrating, head cross answer it is small, it is rapid-action, also reduce destruction of the gastric acid to the alimentation composition, improve bioavilability.The composition, which also has, prevents and treats the eye diseases such as dry and astringent weak ophthalmodynia, dark adaptation, eye-blurred, photophobia, eyes, blink, myopia or macular degeneration, also has anti-aging, anti-inflammatory, the effect for improving immunity.

Description

Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application
Technical field
The present invention relates to a kind of hypoglycemic alimentation compositions.
Background technique
Diabetes are the universally acknowledged diseases for being difficult to cure, and are by inherent cause, immunologic function disorder, microorganism infection And its various virulence factors of toxin, free radical toxin, mental element etc. act on body and lead to hypoinsulinism, insulin A series of metabolic disorder syndromes such as sugar, protein, fat, water and electrolyte of resistance etc. and initiation, clinically with hyperglycemia For main feature, typical patient may occur in which the performances, i.e. " three-many-one-little " symptom such as diuresis, more drinks, more food, syntexis.
Diabetes can cause multiple complications.If diabetes do not obtain enough control, some urgency can be caused Property complication, as hypoglycemia, ketoacidosis, non-ketone hyperosmolar coma, glucose -lipid metabolism disorder and inhereditary material stability drop It is low.Serious long-term complications include: cardiovascular disease, (also known as diabetic nephropathy is that developing country is non-for chronic renal failure The principal disease of aged adult's blinding), neuropathy and microangiopathies.Wherein, microangiopathies may cause erection function Energy obstacle (impotence) and wound are difficult to heal.And foot is difficult to the wound to heal then and may cause gangrene and (is commonly called as " diabetes Foot "), and then lead to patient's amputation.
Currently, the drug for treating diabetes is various, type has Chinese medicine class, western medicine class, the medicine of these treatment diabetes Object has certain curative effect, but haves the defects that certain: western medicine class has certain side effect, such as melbine, can be quickly after intake Blood glucose is reduced, control is bad to easily lead to hypoglycemia；Chinese medicine class treatment speed is slow, and current Chinese medicine material is mostly artificial kind It plants, unsatisfactory curative effect；The health care products such as good propolis, the royal jelly sold in the market, it is expensive, and contain certain sugar, it is not suitable for Diabetes patient's long-term consumption.The insulin of injection mostly contains hormone, can generate adverse effect to human body." megavitamin D3 supplements influence to diabetes rat glycolipid metabolism and DNA damage " in a text, it is noted that large dosage of vitamin D 3 can drop The value of fasting blood glucose, but do not have significant difference, and large dosage of vitamin D 3 can be to causing Serum Calcium Phosphorus unbalance and rouge The side effects such as matter metabolic disorder；In " influence of the vitamin A bound insulin intervention to STZ blood glucose in diabetic rats " text, mention Blood glucose value can be reduced to replenishing vitamins A, but does not have significant difference.It is got over by the research of the Dietary frequency of target spot of intestinal flora Come more, is also increasingly become research hotspot by the concern of scientists.Such as Chinese Tiny ecosystem magazine 2 months 2018 the 30th Rolled up for the 2nd phase the mechanism of action and phase that probiotics prevention blood glucose is referred in " research achievement of the probiotics in Regulation of blood glucose " text Experimental data is closed, but has been only referred to viable bacteria, is not related to probiotics fermention object but, probiotics is influenced by temperature and oxygen, is used Property is restricted.Probiotics fermention object powder is sterilising prods, is not influenced by temperature and oxygen, and application range is wider, more passes through Ji.
Summary of the invention
The object of the present invention is to provide a kind of hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its answer With to meet the needs of people.And this composition also has intestinal health, raising immune, treats the effect of canker sore.
The hypoglycemic vitamin and probiotics fermention product powder alimentation composition, the component including parts by weight:
10 parts~15 parts of vitamin mixed powder
1~5 part of probiotics fermention object powder
0.5 part~70 parts of sugar alcohol
Preferably, further includes:
59~15 parts of disintegrating agent
0.4~10 part of lubricant
The vitamin mixed powder includes vitamin A, vitamin D, vitamin B5 and vitamin B12, weight ratio are as follows:
Vitamin A: vitamin D: vitamin B5: vitamin B12=1:0.001~0.1:5~25:0.0008~0.01；
Preferably, vitamin A: vitamin D: vitamin B5: vitamin B12=vitamin A: vitamine D3: vitamin B5: Vitamin B12=1:0.01~0.03:10~15:0.003~0.004
The vitamin A includes one or more of retinol acetate and beta carotene, and preferably acetic acid view is yellow The mixture of ester and beta carotene, weight ratio are retinol acetate: beta carotene=1:1~4:1
The vitamin D includes one or more of calciferol and vitamine D3；
The vitamin B5 is calcium pantothenate；
The probiotics fermention object powder be lactobacillus plantarum, Lactobacillus salivarius, bifidobacterium longum, lactobacillus acidophilus hair Ferment product, containing lactic acid, victory peptide, mycelial polysaccharides, hydrogen peroxide, ablastins, biacetyl flavonoids, vitamin and minerals etc., The product of Anhui Jin Qiao company offer is provided；
The sugar alcohol is selected from one of sweet and sour sweet dew, antierythrite, D-sorbite, xylitol or a variety of；
The disintegrating agent be selected from cornstarch, sodium carboxymethyl starch, croscarmellose sodium, crospovidone and One of gas-producing disintegrant is a variety of；
The lubricant is selected from magnesium stearate, fumaric acid odium stearate, macrogol, leucine, sucrose ester, rich horse One of sour sodium is a variety of；
The preparation method of hypoglycemic vitamin and probiotics fermention product powder alimentation composition of the invention is conventional Physical mixing processes after mixing, can be used method well known in the art, be prepared into tablet.
Test proves that hypoglycemic vitamin of the invention and probiotics fermention product powder alimentation composition have blood glucose Significant reduction effect, can be used for preparing health-caring product capable of reducing blood sugar；
The invention further relates to a kind of health-caring product capable of reducing blood sugar, including a effective amount of hypoglycemic vitamin and benefit of health care Raw bacterium fermentation material powder alimentation composition and pharmaceutically acceptable carrier, carrier disintegrating agent as mentioned or lubricant One or more of.
The beneficial effects of the present invention are: the present invention is safe and healthy, the present invention can be inhaled in Orally disintegrating by mucous membrane of mouth Take in into blood, head cross answer it is small, it is rapid-action, also reduce destruction of the gastric acid to the alimentation composition, improve bioavilability. The composition, which also has, prevents and treats dry and astringent weak ophthalmodynia, dark adaptation, eye-blurred, photophobia, eyes, blink, myopia or view The eye diseases such as film macular degeneration also have anti-aging, anti-inflammatory, the effect for improving immunity.
Specific embodiment
Embodiment 1
Formula:
Wherein: the vitamin mixed powder includes vitamin A, vitamin D, vitamin B5 and vitamin B12, weight ratio Are as follows:
Vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.01:10:0.004；
The vitamin A is the mixture of retinol acetate and beta carotene, weight ratio are as follows:
Retinol acetate: beta carotene=2:1
Production method: it after each component is mixed, adopts with method known in this field, is prepared into tablet.
Control group 1
In vitamin mixed powder, vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.01:10:0.004, Weight ratio；
Production method: it is adopted after each component is mixed and is prepared into tablet with method known in this field.
Control group 2
Production method: it is adopted after each component is mixed and is prepared into tablet with method known in this field.
Embodiment 2
Vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.03:15:0.003, weight ratio；Sugar alcohol: sweet dew Sugar alcohol: D-sorbite=9:1, weight ratio；
Vitamin A in mixed powder is the mixture of retinol acetate and beta carotene, retinol acetate: β-carrot Element=3:1
Production method: it adopts with method known in this field, is prepared into tablet；
Control group 3
Vitamin A: vitamine D3: vitamin B5: vitamin B12=1:0.03:15:0.003
Sugar alcohol: mannitol: D-sorbite=9:1, weight ratio；
It adopts and is prepared into tablet with method known in this field.
Control group 4
Sugar alcohol: mannitol: D-sorbite=9:1, weight ratio；
It adopts and is prepared into tablet with method known in this field.
Embodiment 3
1. zoopery
(1) animal selects: selecting ICR mouse (offer of zoopery middle school, Shenyang Pharmaceutical University), between weight 18-22g.
(2) drug administration: being all made of gastric infusion, and dosage is expressed as dosage 100mg/kg weight~200mg/kg weight
(3) the drop blood of this composition hyperglycemia model and grouping: is studied using alloxan cause experimental hyperglycemia model Sugar effect.
After ICR mouse fasting 12h, according to dosage alloxan is injected intraperitoneally in 180mg/kg, and mouse tail end takes hematometry after 5d Blood glucose.Blood glucose value is chosen in the mouse of 11.1~24mmol/L, is grouped at random, every group 12, totally 8 groups, blood glucose value between each group Mean value is not statistically significant (P > 0.05).
Be respectively model control group, example 1 group, 2 groups of embodiment, control 1 group, control 2 groups, control 3 groups, control 4 groups, Melbine group；Embodiment group and the daily stomach-filling 150mg/kg of each control group.The daily stomach-filling melbine of melbine group 250mg/kg.Taking 12 mouse that alloxan is not injected intraperitoneally is Normal group；
0.5% sodium carboxymethylcellulose of Normal group and the daily stomach-filling of model control group in equal volume, embodiment group, The product of corresponding dosage is given in stomach-filling respectively for control group and melbine group, 10mL/kg, 1 time a day continuous gavage 8 weeks.
(4) index determining: measuring every group of every daily inleting appetite of animal in experimentation, calculate every group of every mouse be averaged day into Appetite (difference of adjacent two days every group of animal feeds/every group of number of animals, altogether record 8 weeks it is for statistical analysis)；Mouse fasting is not After prohibiting 6~8h of water, cuts tail point and blood blood glucose meter is taken to measure fasting blood-glucose.At administration 8 week, mouse weight is weighed, eyeball is plucked and takes blood, After the static 1h of room temperature, it is centrifugated serum, Elisa kit method measures serum insulin level.
(5) data are analyzed: each group of data is indicated with mean+SD (x ± s), carries out single factor test using SPSS software Variance analysis is compared between multiple groups two-by-two using LSD method, is that difference has conspicuousness with P < 0.05.
(5) experimental result
1 embodiment of table is averaged to mouse and day uses up appetite and changes of weight
Group Quantity Average daily inleting appetite (g) Weight (g) after 8 weeks
Normal group 12 3.24±0.60 26.81±2.29
Model control group 12 4.44±0.78** 56.78±3.40**
Example 1 group 12 4.57±0.72** 63.32±3.36**#
Compare 1 group 12 4.37±0.80** 56.67±1.96**
Compare 2 groups 12 4.45±1.01** 55.98±2.87**
2 groups of embodiment 12 4.50±0.73** 65.28±3.94**#
Compare 3 groups 12 4.46±0.82** 53.90±2.48**
Compare 4 groups 12 4.47±0.74** 55.57±2.90**
Melbine group 12 4.35±0.92** 62.26±4.70**#
Note: compared with Normal group, * * P < 0.01；Compared with model group, #P < 0.05；
2 embodiment of table takes the influence to mouse fasting blood-glucose in 8 weeks
Note: compared with Normal group, * P < 0.05, * * P < 0.01；Compared with model group, #P < 0.05, ##P < 0.01；
Influence of 3 embodiment of table to mice serum insulin level
Group Quantity Serum insulin (ng/mL)
Normal group 12 0.90±1.20
Model control group 12 54.21±39.51**
Example 1 group 12 57.04±28.58**
Compare 1 group 12 84.29±29.47**#
Compare 2 groups 12 87.78±37.43**#
2 groups of embodiment 12 57.67±28.90**
Compare 3 groups 12 89.33±29.05**#
Compare 4 groups 12 88.65±37.81**#
Melbine group 12 66.54±59.00**
Note: compared with Normal group, * * P < 0.01；Compared with model group, #P < 0.05；
Know from table 1, table 2, table 3, embodiment 1 and 2 effect of embodiment are close with melbine group, are better than each control group；
Clinical observation；
1. Lee, female, 69 years old, three is high for many years, and blood glucose is unstable always, by taking embodiment 1 45 days, glucostasis, Frequent micturition, glucose in urine, thirsty symptom obviously disappear, and body is obviously comfortable.Former AC Sugar is 13mmol/L or so, and blood glucose is steady after meal Determine 18.0mmol/L or so, existing AC Sugar stablizes 8mmol/L or so, after meal glucostasis 11mmol/L or so.It takes 60 days AC Sugar stablizes 7.5mmol/L or so afterwards, after meal glucostasis 10.5mmol/L or so.In the process, patient feeds back immunity It gets a promotion.
2. Mr. Wang, male, 65 years old, many years diabetes, by taking embodiment 2 45 days, glucostasis, three-many-one-little symptom It is basic to disappear.Former AC Sugar is 12.5mmol/L or so, after meal glucostasis 17.0mmol/L or so, and existing AC Sugar is stablized 7.0mmol/L or so, after meal glucostasis 9.5mmol/L or so；After taking 60 days, AC Sugar stablizes 6.5mmol/L or so, Glucostasis 9.0mmol/L or so after meal.In the process, patient's physical strength is promoted, and is moved not easy to fatigue.

Claims (10)

1. hypoglycemic vitamin and probiotics fermention object powder alimentation composition, which is characterized in that the component including parts by weight:
10 parts~15 parts of vitamin mixed powder
1~5 part of probiotics fermention object powder
0.5 part~70 parts of sugar alcohol.
2. hypoglycemic vitamin according to claim 1 and probiotics fermention object powder alimentation composition, which is characterized in that Further include:
59~15 parts of disintegrating agent
0.4~10 part of lubricant.
3. hypoglycemic vitamin according to claim 1 and probiotics fermention object powder alimentation composition, which is characterized in that The vitamin mixed powder includes vitamin A, vitamin D, vitamin B5 and vitamin B12, weight ratio are as follows:
Vitamin A: vitamin D: vitamin B5: vitamin B12=1:0.001~0.1:5~25:0.0008~0.01.
4. hypoglycemic vitamin according to claim 1 and probiotics fermention object powder alimentation composition, which is characterized in that Vitamin A: vitamin D: vitamin B5: vitamin B12=vitamin A: vitamine D3: vitamin B5: vitamin B12=1: 0.01~0.03:10~15:0.003~0.004.
5. hypoglycemic vitamin according to any one of claims 1 to 4 and probiotics fermention object powder alimentation composition, It is characterized in that, the vitamin A includes one or more of retinol acetate and beta carotene.
6. hypoglycemic vitamin according to claim 5 and probiotics fermention object powder alimentation composition, which is characterized in that The vitamin A is the mixture of retinol acetate and beta carotene, and weight ratio is retinol acetate: beta carotene= 1:1~4:1.
7. hypoglycemic vitamin according to any one of claims 1 to 4 and probiotics fermention object powder alimentation composition, It is characterized in that, the vitamin D includes one or more of calciferol and vitamine D3.
8. hypoglycemic vitamin according to any one of claims 1 to 4 and probiotics fermention object powder alimentation composition, It is characterized in that, the vitamin B5 is calcium pantothenate.
9. described in any item hypoglycemic vitamins and probiotics fermention object powder alimentation composition exist according to claim 1~8 Prepare the application in health-caring product capable of reducing blood sugar.
10. a kind of health-caring product capable of reducing blood sugar, raw including a effective amount of hypoglycemic dimension according to any one of claims 1 to 8 of health care Element and probiotics fermention object powder alimentation composition and pharmaceutically acceptable carrier.
CN201910708111.0A 2019-08-01 2019-08-01 Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application Pending CN110384240A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910708111.0A CN110384240A (en) 2019-08-01 2019-08-01 Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910708111.0A CN110384240A (en) 2019-08-01 2019-08-01 Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application

Publications (1)

Publication Number Publication Date
CN110384240A true CN110384240A (en) 2019-10-29

Family

ID=68288272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910708111.0A Pending CN110384240A (en) 2019-08-01 2019-08-01 Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application

Country Status (1)

Country Link
CN (1) CN110384240A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111150059A (en) * 2020-01-19 2020-05-15 西倍健生物科技(深圳)有限公司 Special probiotic bacterium composition for women and application thereof
CN114376135A (en) * 2020-10-16 2022-04-22 杭州创盈生物科技有限公司 Intestine-moistening bowel-relaxing probiotic composition solid beverage and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039531A1 (en) * 2006-09-27 2008-04-03 Little Calumet Holdings, Llc Probiotic oral dosage forms
CN106036911A (en) * 2016-06-21 2016-10-26 广州宇晟生物科技有限公司 Probiotics diet composition and functional food for regulating blood glucose level
CN106039050A (en) * 2016-05-26 2016-10-26 三株福尔制药有限公司 Composition of probiotic-fermented corn stigma as well as preparation method and application of composition
CN107927794A (en) * 2017-12-20 2018-04-20 北京康比特体育科技股份有限公司 A kind of probiotics functional food composition and preparation method thereof
US20180125901A1 (en) * 2016-11-03 2018-05-10 Cell Biotech Co., Ltd. Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039531A1 (en) * 2006-09-27 2008-04-03 Little Calumet Holdings, Llc Probiotic oral dosage forms
CN106039050A (en) * 2016-05-26 2016-10-26 三株福尔制药有限公司 Composition of probiotic-fermented corn stigma as well as preparation method and application of composition
CN106036911A (en) * 2016-06-21 2016-10-26 广州宇晟生物科技有限公司 Probiotics diet composition and functional food for regulating blood glucose level
US20180125901A1 (en) * 2016-11-03 2018-05-10 Cell Biotech Co., Ltd. Composition for preventing or treating bone disease, obesity and lipid-related metabolic disease
CN107927794A (en) * 2017-12-20 2018-04-20 北京康比特体育科技股份有限公司 A kind of probiotics functional food composition and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111150059A (en) * 2020-01-19 2020-05-15 西倍健生物科技(深圳)有限公司 Special probiotic bacterium composition for women and application thereof
CN114376135A (en) * 2020-10-16 2022-04-22 杭州创盈生物科技有限公司 Intestine-moistening bowel-relaxing probiotic composition solid beverage and preparation method thereof

Similar Documents

Publication Publication Date Title
CN103238897B (en) Composite plant solid drink suitable for diabetic patients
CN102757508B (en) A kind of Radix Ophiopogonis polysaccharide extract has the application in the foodstuff additive of weight losing function, healthcare products or medicine in preparation
TWI721248B (en) Anti-fatigue composition used for increasing endurance performance
WO2018090983A9 (en) Saponin compound for improving intestinal microflora, preparation method and use thereof
CN113274481B (en) Composition for regulating blood sugar and preparation method and application thereof
CN112263669A (en) Oligopeptide traditional Chinese medicine probiotic compound for relieving hyperuricemia
CN114343183A (en) Polysaccharide and probiotic composition for regulating and controlling intestinal anti-constipation activity
KR20170028486A (en) Composition for Preventing, Treating or Improving Menopausal Syndrome comprising Sparassis crispa Wulf.: Fr. and Lactic Acid Bacteria as Active Ingredient
TWI627959B (en) Use of lactobacillus reuteri gmnl-263 for manufacturing composition for increasing expression of ldl-r and cyp7a1 in liver in high-fat diet individual
CN110384240A (en) Hypoglycemic vitamin and probiotics fermention object powder alimentation composition and its application
CN111870609A (en) Intestinal flora regulator and application thereof
CN107223981B (en) Composition containing soybean polypeptide argatroxin and preparation method thereof
CN106174484A (en) There is the enzyme composition of cough and asthma relieving efficacy, effervescent granule and preparation method
CN107455739A (en) A kind of three high drop health care nutrition powder
CN102631466A (en) Health care product for regulating blood lipid and preparation method thereof
CN109045070A (en) A kind of composition for preventing and treating non-alcoholic fatty liver disease
CN108653298A (en) Monosaccharide composition, pharmaceutical preparation and its application
CN111281902A (en) Application of lithocarpus litseifolius or active extract thereof
CN102225082B (en) Medicament for preventing and treating diabetes and complications thereof and preparation method thereof
CN105194658A (en) Traditional Chinese medicinal preparation for treating obesity and enhancing physique and preparation method of traditional Chinese medicinal preparation
CN115177658B (en) Composition for reducing blood sugar
CN112336754B (en) Application of cladosporium compound microbial inoculum in preparation of medicines for treating metabolic diseases and culture method
CN106387363A (en) Iodine-enriched selenium-enriched chromium-enriched strengthening agent for eggs, as well as preparation method and use method of iodine-enriched selenium-enriched chromium-enriched strengthening agent
US20240009261A1 (en) Prebiotic compositions and method for weight loss by using the same
CN106798826A (en) Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191029

RJ01 Rejection of invention patent application after publication